Differences in presenting features, outcome and prognostic models in patients with Primary Myelofibrosis and post Polycythemia vera/post Essential Thrombocythemia Myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study

Recently, the Myelofibrosis Secondary to PV and ET Prognostic Model (MYSEC-PM) was introduced to assess prognosis in myelofibrosis (MF) secondary to Polycythemia Vera and Essential Thrombocythemia (post-PV/post-ET MF), replacing the IPSS/DIPSS that was applied for primary MF (PMF). In a cohort of 421 ruxolitinib-treated patients (post-PV/post-ET MF: 44.2%), we evaluated: 1) disease phenotype, responses and toxicity to ruxolitinib; 2) performance of the MYSEC-PM in post-PV/post-ET MF. While the IPSS failed to correctly stratify post-PV/post-ET MF patients at diagnosis, the MYSEC-PM identified four risk categories projected at significantly different survival probability (p

Source: Seminars in Hematology - June 4, 2018 Category: Hematology Authors: Francesca Palandri, Giuseppe Alberto Palumbo, Alessandra Iurlo, Nicola Polverelli, Giulia Benevolo, Massimo Breccia, Elisabetta Abruzzese, Mario Tiribelli, Massimiliano Bonifacio, Alessia Tieghi, Alessandro Isidori, Bruno Martino, Nicola Sgherza, Mariella Source Type: research